Polycyclic aromatic hydrocarbons (PAHs) are known immunotoxins and carcinogens. Our laboratory and others have demonstrated that metabolism of these compounds by CYP1B1 is required for carcinogenicity and immunotoxicity to occur. Previously, our laboratory reported significantly decreased bone marrow cellularity in mice following 7,12-dimethlybenz[a]anthracene (DMBA) administration. In addition, we have observed that DMBA causes apoptosis via activation of both caspase-8 and -9 in pre-B cells co-cultured with bone marrow stromal cells in vitro. In this study, we investigated the importance of the p53 protein in the bone marrow response to DMBA. Through the use of p53 gene knockout mice, we demonstrated that the effect of DMBA on bone marrow cellularity is p53-dependent. In addition, apoptosis of primary cultures of progenitor B cells cultured with bone marrow stromal cells and DMBA is also p53-dependent. The results of this study provide evidence for the importance of p53 in the signaling pathways by which PAHs cause immunotoxicity.
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental contaminants, generated by the incomplete combustion of organic materials, that have been demonstrated to be both carcinogenic and immunotoxic (Collins et al., 1998) . Humans are exposed to these compounds from a variety of sources, including incinerators and various other industrial processes. One of the main routes of exposure is through the diet (Phillips, 1999) . Charbroiling and smoking of meats can generate high levels of PAHs, and PAHs can be found in fruits and vegetables grown in areas of high industrial pollution (Kazerouni et al., 2001) . Smoking also accounts for a large amount of human exposures (Rodgman et al., 2000) .
7,12-Dimethylbenz[a]anthracene (DMBA) and benzo-[a]pyrene (B[a]P) are the prototypical and best characterized PAHs. These compounds can have significant effects on both humoral and cell-mediated immunity (Burchiel et al., 1990; Ward et al., 1984) . The mechanisms responsible for the immunotoxicity of these compounds are not completely understood. It has been demonstrated that metabolic activation by the cytochrome P450 1B1 (CYP1B1) enzyme is required for their immunotoxic effect (Heidel et al., 1999 (Heidel et al., , 2000 Mann et al., 1999; White et al., 1985) . The role of the arylhydrocarbon receptor (AhR) in the immunotoxic effects of PAHs is a source of debate. When the AhR binds PAHs, it translocates to the nucleus and induces transcription of a variety of Ah-responsive genes, including P450 cytochromes such as CYP1B1. However, bone marrow stromal cells express a high basal level of CYP1B1 and are able to metabolize PAHs in the absence of a functional AhR (Heidel et al., 2000) . In addition, 2,3,7,8-tetrachlorodibenzo-p-dioxin, or TCDD (i.e., dioxin), binds the AhR with a greater affinity than PAHs but is not metabolized and has different effects on the immune system than do the PAHs (Laupeze et al., 2002; Okey et al., 1984a,b) .
PAHs are both carcinogenic and immunotoxic, although the doses required for these two effects may differ (White et al., 1985) . The mechanisms of carcinogenicity and the mutagenic properties of PAHs have been studied in greater detail than their effects on the immune system. As is the case for their immunotoxic effects, PAHs must be metabolically activated by the cytochrome P450 family of monooxygenases to be carcinogenic (Badawi et al., 1996; Cavalieri and Rogan, 1992) . These activated metabolites then form adducts with DNA and cause mutations. Mutations in key regulatory genes, in addition to changes in gene expression mediated by binding of the AhR, are thought to be the major mechanisms responsible for the carcinogenic effects of PAHs (White et al., 1994) . The fact that these two disparate effects of PAHs are interrelated may provide some clues as to the mechanism of immunotoxicity for these compounds.
The p53 tumor-suppressor protein is responsible for regulating cellular responses to DNA damage and progression through the cell cycle (Hickman et al., 2002; Sharpless and DePinho, 2002) . The importance of p53 in maintaining a normal pattern of cellular proliferation is illustrated by p53 being one of the most frequently mutated genes found in tumor biopsies and transformed cell lines (Gupta et al., 1993) . In addition, p53 plays a crucial role as a "gatekeeper" of genomic integrity. If DNA has been damaged in such a way that it cannot be effectively repaired, p53 will initiate apoptosis to prevent the damaged cell from proliferating. Several DNAdamaging agents (e.g., cisplatin, etoposide) have been demonstrated to induce p53 and activate apoptosis in a p53-dependent manner (Karpinich et al., 2002; Siemer et al., 1999) .
The B-cell lineage constitutes the main component of the humoral immune system. In the bone marrow, there is a specific differentiation pathway for B cells that begins with the common lymphoid progenitor and ends with immature IgM expressing B cells, which then leave the bone marrow to populate the spleen and lymph nodes (Hardy and Hayakawa, 2001 ). B-cell development is driven by the interaction of the progenitor B cells with bone marrow stromal cells that secrete cytokines and express adhesion molecules that drive the differentiation of the progenitor B cells. Disruption of this interaction via exogenous toxicants could have profound effects on B-cell lymphopoiesis and can result in the impairment of antibody production directed against pathogens. Previously, our laboratory demonstrated that DMBA causes apoptosis in pre-B cells when the latter are co-cultured with bone marrow stromal cells that metabolize DMBA via CYP1B1 (Heidel et al., 1999 (Heidel et al., , 2000 Page et al., 2002) . Our hypothesis is that DMBA disrupts hematopoiesis in the bone marrow and affects normal B-cell development by targeting discreet cell populations along the B-cell lineage continuum and further, that this disruption is dependent on the presence of functional p53.
The goal of this study was to determine whether the effects of DMBA on the murine bone marrow are dependent on activation of p53. To accomplish this goal, we utilized homozygous null p53 mice that were treated with a single bolus injection of DMBA. We also investigated the importance of p53 in the progenitor B cell in their response to stromal cells and DMBA in vitro. We present evidence that the effects of DMBA on bone marrow cells in vivo and progenitor B cells in vitro are largely dependent on the presence of functional p53 protein.
MATERIALS AND METHODS

Animals and treatments.
A breeding pair of B6.129S-2Trp53 null mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Homozygous mice (p53 Ϫ/Ϫ ) were produced by breeding heterozygous mice (p53 ϩ/-), and the litters were genotyped by PCR. Littermates that were genotyped as p53 ϩ/ϩ were used as wild-type (WT) control mice in our experiments. The animals were housed at the Association for Assessment and Accreditation of Laboratory Animal Care International certified animal care facility of the University of Wisconsin-Madison School of Veterinary Medicine. All animal use and care was conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals.
At 5-7 weeks of age, male or female p53 Ϫ/Ϫ and p53 ϩ/ϩ C57Bl/6 mice were injected ip with either DMBA (50 mg/kg) or vehicle (olive oil). After 48 h, the mice were euthanized; their femurs, tibias, and sternums were dissected free of muscle tissue; and the ends were removed with a scalpel. For total cell counts, the femurs were flushed with RPMI 1640 with 5% FBS, using a 25-gauge needle. The cells were then sequentially passed through a 25-gauge needle and a 22-gauge needle to generate single-cell suspensions. The cells were then centrifuged, and the RBCs were lysed using ACK buffer (150 mM NH 4 Cl, 1.0 mM KHCO 3 , and 100 mM Na 2 EDTA, pH 7.3). The white cells were resuspended in 5 ml of RPMI 1640 and centrifuged again. The cell pellets were then resuspended in 5 ml of RPMI 1640, and an aliquot was removed for enumeration of viable cells using a hemacytometer and Trypan blue exclusion.
Histopathology and cytology. The sternums were removed and fixed in ice-cold 4% phosphate-buffered paraformaldehyde, decalcified for 30 min (Formacal-4, Decal Co., Congers, NY), embedded in paraffin, sectioned at 2-M thickness, and stained with H&E. Bone marrow smears were prepared by cutting a tibia longitudinally, streaking the exposed bone marrow onto a glass slide with a sable-hair brush, and allowing the cell smears to air dry. These were subsequently stained with Wright's stain and examined microscopically, as described previously (Heidel et al., 2000; Page et al., 2002) . The sternum sections and the bone marrow smears were examined microscopically and scored for cell type by an American College of Veterinary Pathologists board-certified pathologist (P.S.M.). For the bone marrow differential cell counts, a total of 500 cells were counted, and the percentage of cells in each of the following categories was enumerated: erythroid precursors, proliferating granulocytes (myeloblast, progranulocytes, myelocytes), mature granulocytes (metamyelocytes, bands, segmented neutrophils), and lymphoid cells. The total cell number for each category was derived by multiplying the percentage of each cell type present in the Wright-stained bone marrow smears of the tibia by the total number of bone marrow cells generated after flushing the marrow from two femurs per mouse. Abnormalities in cellular development in both the erythrocytic and granulocytic lineages were identified and recorded.
Primary culture of bone marrow progenitor B lymphocytes. Long-term bone marrow cultures (LTBMC) were established according to the protocol of Witte (Whitlock et al., 1984) . Briefly, cells were flushed from the mouse femurs with sterile, ice-cold, RPMI 1640 (5% FBS) (Mediatech, Herndon, VA), then centrifuged and resuspended in 1 ml RPMI 1640 (5% FBS). An aliquot of cells was then diluted 1:10 with crystal violet (0.01% w/v crystal violet, 3% acetic acid) and counted using a hemacytometer. Cell density was adjusted to 1 ϫ 10 6 cells/ml, and the cells were cultured in RPMI 1640 with 5% FBS at 37°C. The media were changed each week (75% fresh media in total volume). After 2 weeks of culture, the media were supplemented with 4 ng/ml of recombinant murine IL-7 (R&D Systems, Minneapolis, MN). By 3 weeks, progenitor B cells were visible in suspension and loosely adherent to the stromal cells.
The phenotype of the progenitor B cells from the LTBMCs was then verified using fluorochrome-conjugated primary antibodies specific for pre-B cell surface markers and flow cytometric analysis (Thurmond and Gasiewicz, 2000) . The antibodies used were IgM (clone AF6-78), B220 (clone RA3-6B2), AA4.1 (clone AA4.1), and CD19 (clone 1D3). All antibodies were purchased from Pharmingen (San Diego, CA). Briefly, the cells were isolated from the LTBMCs by gentle agitation, washed twice with PBS ϩ 2% BSA, and fixed with 4% paraformaldehyde. The cells were then washed again and stained with the appropriate antibodies. The cells were then washed twice and stored at 4°C until FACS analysis was performed. The data were analyzed using Cellquest Pro software (BD Biosciences, San Jose, CA). After phenotyping an aliquot of the cells harvested from the LTBMCs, the remainder of the cells were then used for experiments.
Propidium iodide staining. The immunophenotyped pre-B cells were removed from the LTBMCs and co-cultured with monolayers of bone marrow stromal cells (BMS2 cell line) that were at approximately 75% confluence. The BMS2 cell line was generously provided by Dr. Paul Kincade (Oklahoma Medical Research Foundation, Oklahoma City, OK). The cultures were incubated with the indicated concentrations of DMBA for 24 h; pre-B cells were then removed from the BMS2 monolayers by gentle agitation, as described previously (Page et al., 2002) . The detached cells were centrifuged for 5 min at 1200 rpm and washed once in ice-cold PBS ϩ 2% bovine serum albumin. Cells were fixed in 1 ml of 80% ice-cold ethanol for 30 min at -20°C, then centrifuged for 5 min at 1200 rpm and resuspended in phosphate-citric acid buffer (0.192 M Na 2 HPO 4 , 4mM citric acid, pH 7.8) for 5 min at room 86 temperature. After centrifugation, the cells were resuspended in 0.5 ml of propidium iodide staining solution (33 g/ml propidium iodide; Sigma-Aldrich), 1 mg/ml RNase A, 0.2% Triton X-100, in PBS) and analyzed in a Becton/Dickinson FACScan flow cytometer (BD Biosciences, San Jose, CA). Because cells undergoing DNA fragmentation and apoptosis exhibit weaker propidium iodide fluorescence than do cells in the G o /G 1 cell cycle, a decrease in PI fluorescence is indicative of the morphological changes consistent with apoptosis (Yamaguchi et al., 1997) .
RESULTS
Bone Marrow Cell Depletion Does Not Occur in DMBA-
Treated p53 Null Mice p53 null and WT mice were injected ip with 50 mg/kg DMBA or vehicle control and euthanized after 48 h. A 48 h exposure time was chosen because in previous experiments we have observed significant depletion of bone marrow cellularity at this time point (Heidel et al., 2000) . The bone marrow cells were isolated and counted, then live cells were discriminated from dead cells by Trypan blue exclusion. There was a significant decrease in the number of viable cells recovered from the bone marrow of DMBA-treated WT mice, as compared with vehicle-treated mice (Fig. 1) . Both the total number of cells and the percentage of viable cells were decreased in DMBA-treated versus vehicle control WT mice (data not shown). In contrast, there was no difference in the numbers of bone marrow cells recovered from DMBA-and vehicle-treated p53 null mice (Fig. 1) , nor was there any difference in bone marrow cell viability between vehicle-or DMBA-treated p53 null mice (data not shown).
Histopathological Analysis of Murine Bone Marrow
Wright-stained bone marrow smears from the tibias of WT mice exhibited abnormal large blast cells that have been characterized previously by extensive cytochemical staining as being members of the granulocyte lineage (Fig. 2C) (Heidel et al., 2000) . These blast cells were absent from the WT control bone marrow (Fig. 2D) and both the DMBA-treated and control p53 null mice ( Figs. 2A and 2B) . DMBA-treated WT mice also exhibited aberrant multinucleated granulocytes that were absent in the WT controls and the DMBA-treated p53 null mice (Figs. 2E and 2F) .
Bone marrow sections from the sternums of WT DMBAtreated mice exhibited a marked hypocellularity when compared with both untreated WT marrow and either treated or untreated p53 null marrow (Fig. 3) . These histopathological observations confirm the decreased numbers of viable cells recovered from the femurs of DMBA-treated mice (Fig. 1) . The WT DMBA-treated murine bone marrow also exhibited dilated sinusoids with extensive erythrocyte infiltration, which was not observed in treated/untreated p53 knockout bone marrow (Fig. 3C) .
DMBA-Induced Depletion of Specific Cell Populations in the Bone Marrow Is p53-Dependent
Wright-stained bone marrow smears were prepared from the tibias of each mouse, and the cells were assigned to the erythroid, granulocyte, or lymphocyte lineages by a boardcertified veterinary clinical pathologist (P.S.M.). The granulocytic cells were classified as mature (postmitotic and including metamyelocytes, bands, and segmented neutrophils) or immature cells (mitotic and including myeloblasts, progranulocytes, and myelocytes). DMBA treatment of WT mice significantly decreased the number of erythroid precursors in the bone marrow of WT but not p53 null mice (Fig. 4A) . The numbers of mature granulocytes were also decreased in the bone marrow of DMBA-treated WT mice (Fig. 4C) . Although there was a slight decrease in the numbers of immature granulocytes in the WT DMBA-treated mice, it was not statistically significant (Fig. 4B) . The large blast cells that were observed in the DMBA-treated WT mice (Figs. 2C and 2F) were recorded as immature granulocytes, which might explain the lack of a significant decrease in the immature granulocytes. In addition, there was also a p53-dependent significant (p Ͻ 0.05) decrease in the lymphocyte population in the DMBA-treated WT mice (Fig. 4D) , which is consistent with the results we have previously reported (Heidel et al., 2000) .
DMBA Does Not Induce Apoptosis in p53 Null Bone Marrow B-Cell Cultures
We have previously reported that the murine pre-B cell line (70Z3) undergoes apoptosis when it is cultured with bone
FIG. 1.
There is no change in total live bone marrow cells after DMBA treatment of p53 null mice. p53 null and WT mice were injected ip with DMBA (50 mg/kg). The bone marrow cells were harvested 48 h later and enumerated using a hemacytometer. Live cells were differentiated from dead cells through Trypan blue exclusion. The data are presented as the mean Ϯ SEM number of live cells present in the two femurs of each mouse (n ϭ 6). Data were analyzed using the unpaired t-test. Asterisk indicates data that are statistically different from vehicle control (oil-treated) mice, p Ͻ 0.05. 87 marrow stromal cells and DMBA. To determine whether this process is p53-dependent, bone marrow cells from C57Bl/6 mice were harvested and cultured in vitro with IL-7 to stimulate the production of pre-B cells. The B cells were phenotyped using surface marker staining and were found to be B220 ϩ , IgM -, AA4.1 ϩ , and CD19 ϩ (Fig. 5 ). This expression pattern is consistent with the pre-B cell stage of B-cell development (Thurmond and Gasiewicz, 2000) .
These primary pre-B cells were then co-cultured with a murine bone marrow stromal cell line (BMS2) in the presence of DMBA and assessed for apoptosis by propidium iodide staining. We found that DMBA-induced apoptosis in pre-B cells derived from WT mice but not from p53 null mice (Fig.  6) . Interestingly, the WT cells did not exhibit a dose-response relationship between DMBA concentration and numbers of apoptotic cells. Perhaps the primary bone marrow pre-B cells are very sensitive to DMBA, and the doses tested were all above the threshold needed to achieve a maximal response.
DISCUSSION
Previous research into the mechanisms of PAH-mediated bone marrow toxicity has focused on the role of PAH metabolism by the CYP450 enzymes or the binding of PAH and activated metabolites by the AhR. In our laboratory and others, it has been demonstrated that PAHs must be metabolized by CYP1B1 in order to be immunotoxic (Heidel et al., 1999 (Heidel et al., , 2000 Mann et al., 1999; White et al., 1985) . In this study, we have focused on the contributions of p53, one of the key regulators of cell death/survival after toxic insult. The results presented here demonstrate the need for p53 protein in DMBAmediated bone marrow toxicity. Through the use of genedisrupted mice, we have observed that the toxic effects of DMBA on the murine bone marrow and on primary cultures of pre-B cells are absent in p53 null mice.
We have further characterized the effects of DMBA on the bone marrow with respect to the cell type. Significantly, we   FIG. 2 . DMBA treatment affects the cellularity in tibial bone marrow smears from WT but not p53 null mice. Wrightstained bone marrow smears were prepared from the tibias of p53 null (A, B, and E) and WT (C, D, and F) mice 48 h after they were injected ip with 50 mg/kg of DMBA (A, C, E, and F) or vehicle (B and D). DMBA-treated WT mice exhibited abnormal granulocyte maturation characterized by large blast cells of the granulocyte lineage (C and F, black arrows) and aberrant, multinucleated granulocytes (F, right arrow). As a result of the myeloid depletion, small lymphocytes appeared to be relatively more prominent (C, white arrows). The photomicrographs above are representative examples of mice used to obtain the data in Figure 1 . A, B, C, and D: ϫ250 magnification; E and F: ϫ400 magnification. 88 noted a p53-dependent decrease in erythroid precursors after DMBA treatment. Functional p53 was required for the depletion of all cell lineages examined (i.e., granulocytes, erythroid precursors, and lymphocytes). This indicates that the majority of DMBA-induced bone marrow toxicity may be mediated through a p53-dependent pathway, even in disparate cell types. To the best of our knowledge, this is the first observation of the p53 dependence of DMBA-mediated bone marrow toxicity in vivo.
The p53 protein plays a major role in the regulation of the apoptotic cascade, so the observation that ablation of its activity protects against DMBA-mediated toxicity is consistent with its known biological function. It has been very difficult to detect apoptosis in the murine bone marrow in vivo after DMBA treatment. One reason for this might be that bone marrow macrophages phagocytose apoptotic cells very efficiently, so that at any given time there is a very small population of apoptotic cells present. The results of this study, in conjunction with our previous observations using cell-culture model systems, support the notion that DMBA causes apoptosis and/or growth arrest in the murine bone marrow.
It has been previously reported that activation of the nuclear transcription factor NF-B protects pre-B cells against PAHinduced apoptosis. Mann et al. reported that PAHs suppress NF-B and that suppression of NF-B by specific inhibitors leads to pre-B cell apoptosis (Mann et al., 2001) . NF-B activation is, in general, an anti-apoptotic signal, whereas p53 activation is pro-apoptotic (Beg and Baltimore, 1996; Bertrand et al., 1998; Levine, 1997) . Other investigators have proposed (HolmesMcNary et al., 2001; Webster and Perkins, 1999) . In other systems, the opposing regulation of p53 and NF-B has been proposed as a mechanism of apoptosis induction (HolmesMcNary et al., 2001) . These findings and the results of this study suggest that PAH metabolites might cause apoptosis in pre-B cells by both inducing p53 and inhibiting the activity of NF-B.
DMBA is also carcinogenic, and p53 is often mutated in transformed cells (Gupta et al., 1993) . The requisite role of p53 in bone marrow toxicity suggests that the decreased cellularity noted in WT mice may reflect the efforts of the immune system to protect itself from the generation of leukemias and lymphomas following PAH exposure. p53-Induced apoptosis occurs when the levels of DNA adduct formation caused by DNAdamaging agents (e.g., radiation, toxins, etc.) overwhelm the DNA repair machinery of the cell. If PAH metabolites form mutation-causing adducts in the p53 gene, the cells of the immune system may lose the protective mechanism of eliminating aberrant cells, as suggested by the absence of bone marrow hypocellularity in the p53 null mice. This could, in turn, lead to a higher incidence of tumor formation in these mice after DMBA exposure. Indeed, it has been reported that p53 null mice have a higher incidence of mammary tumors after DMBA administration and are more susceptible to teratogenic malformation after ionizing radiation than are WT mice (Jerry et al., 2000; Kato et al., 2001) .
Although it is possible that the toxicity observed in the bone marrow after DMBA exposure might protect against leukemia or lymphoma, disruption of B-cell development can have profound deleterious effects on acquired immunity. Previous studies have documented a decrease in B-cell reactivity and IgM production among workers occupationally exposed to PAHs (Winker et al., 1997) . In addition, it has also been demonstrated that the potent AhR agonist, TCDD, alters B-cell populations (Thurmond and Gasiewicz, 2000) . The precise mechanisms underlying these adverse effects on B cells are unknown. In this study, we demonstrate that the effects of DMBA on the murine bone marrow are dependent on functional p53. Previous work in our laboratory found that the interferon-inducible kinase (PKR) is upregulated in pre-B cells in response to DMBA treatment (Page et al., 2002) . This observation is important because PKR has been shown to activate p53 (Cuddihy et al., 1999a,b) . Coupled together, these observations point to a possible pathway of DMBA-mediated bone marrow toxicity. Our working model is that metabolites of DMBA stimulate bone marrow cells to release a soluble factor (e.g., cytokine or chemokine) that leads to PKR activation, which in turn activates p53 and causes apoptosis in the affected cell types.
In conclusion, this study has demonstrated that p53 protein is necessary for bone marrow depletion of granulocytic, erythroid, and lymphocytic cells after DMBA treatment. In addition, we have demonstrated that pre-B cells derived from the bone marrow of p53 null mice are also resistant to DMBAmediated apoptosis in vitro. These studies provide new insights into the molecular mechanisms underlying DMBA-induced immunotoxicity.
